image

Immuno-Oncology

Innovative Drugs Designed to Improve Patients’ Lives

Our clinical-stage pipeline includes four internally discovered and wholly owned drug-candidates designed to treat patients with hematologic malignancies and solid tumors. It comprises both Targeted Protein Degraders to eliminate disease causing proteins and E3 ligase inhibitors that target key control elements in immune regulation (Targeted Protein Elevation). Drug discovery alliances with Gilead Sciences and Sanofi further enhance our pipeline, each focusing on the discovery and development of Targeted Protein Degraders against a set of unique targets.

Building Immunity to Cancer: Nurix’s Immuno-Oncology Program

Targeted Protein Elevation: CBL-B Inhibition

Casitas B-lineage lymphoma proto-oncogene-b (CBL-B) is an E3 ligase that is expressed in immune cells and in the context of cancer, acts as a brake on the immune system. CBL-B functions as an intracellular checkpoint that negatively regulates T cell activation, NK cell activity, and immune response through degradation of specific proteins.

Conversely, inhibition of CBL-B with a small molecule drug activates T cells, a goal in the treatment of cancer, where T cells and the entire immune system can be mobilized to destroy a tumor. Nurix has developed two CBL-B inhibitors, NX-1607 for oral administration and NX-0255 for Adoptive Cell Therapy.

Drug CandidateTarget (Delivery)Therapeutic AreaDiscoveryIND enablingPhase 1Phase 2Phase 3
Clinical Pipeline
NX-2127 Degrader BTK + IKZF B-cell malignancies

 

NX-5948 Degrader BTK (Oral) B-cell malignancies and autoimmune disease

 

NX-1607 Inhibitor CBL-B (Oral) Immuno-oncology

 

DeTIL-0255 Cell Therapy Adoptive cell therapy with ex vivo CBL-B inhibition Gynecologic malignancies

 

Drug CandidateTarget (Delivery)Therapeutic AreaDiscoveryIND enablingPhase 1Phase 2Phase 3
Discovery Pipeline
Wholly Owned Multiple targets* Undisclosed

 

Gilead Sciences 5 targets Undisclosed

 

Sanofi 5 targets Undisclosed

 

Candidate / TargetPhase
Clinical Pipeline
NX-2127 Degrader
BTK + IKZF
Phase 1
NX-5948 Degrader
BTK (Oral)
Phase 1
NX-1607 Inhibitor
CBL-B (Oral)
Phase 1
DeTIL-0255 Cell Therapy
Adoptive cell therapy with ex vivo CBL-B inhibition
Phase 1
Discovery Pipeline
Wholly Owned
Multiple targets*
Discovery
Gilead Sciences
5 targets
Discovery
Sanofi
5 targets
Discovery

NX-1607 (oral CBL-B inhibitor for solid tumors)

NX-1607 is an oral, small molecule CBL-B inhibitor. In preclinical animal models of both colorectal cancer and triple negative breast cancer, NX-1607 demonstrates anti-tumor activity and prolongs survival. The combination of NX-1607 with an anti-PD-1 antibody provides additional benefit in animal models. The anti-tumor activity of NX-1607 is dependent on both CD8+ T cells and NK cells.

We are planning to develop NX-1607 in multiple solid tumors as monotherapy or in combination with other complementary therapies such as anti-PD-1 antibodies. A Phase 1 clinical trial of NX-1607 as a single agent therapy in multiple oncology indications is ongoing.